These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31127079)

  • 1. Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment.
    Chaudhury S; Brookes KJ; Patel T; Fallows A; Guetta-Baranes T; Turton JC; Guerreiro R; Bras J; Hardy J; Francis PT; Croucher R; Holmes C; Morgan K; Thomas AJ
    Transl Psychiatry; 2019 May; 9(1):154. PubMed ID: 31127079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
    Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
    Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic effects on the risk of Alzheimer's disease in the Japanese population.
    Kikuchi M; Miyashita A; Hara N; Kasuga K; Saito Y; Murayama S; Kakita A; Akatsu H; Ozaki K; Niida S; Kuwano R; Iwatsubo T; Nakaya A; Ikeuchi T; ;
    Alzheimers Res Ther; 2024 Feb; 16(1):45. PubMed ID: 38414085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease.
    Cardoso R; Lemos C; Oliveiros B; Almeida MR; Baldeiras I; Pereira CF; Santos A; Duro D; Vieira D; Santana I; Oliveira CR
    J Alzheimers Dis; 2020; 78(2):587-601. PubMed ID: 33016906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
    Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
    Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease.
    Carrasquillo MM; Crook JE; Pedraza O; Thomas CS; Pankratz VS; Allen M; Nguyen T; Malphrus KG; Ma L; Bisceglio GD; Roberts RO; Lucas JA; Smith GE; Ivnik RJ; Machulda MM; Graff-Radford NR; Petersen RC; Younkin SG; Ertekin-Taner N
    Neurobiol Aging; 2015 Jan; 36(1):60-7. PubMed ID: 25189118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition.
    Leonenko G; Shoai M; Bellou E; Sims R; Williams J; Hardy J; Escott-Price V;
    Ann Neurol; 2019 Sep; 86(3):427-435. PubMed ID: 31199530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a late onset Alzheimer's disease candidate risk variant at 9q21.33 in Polish patients.
    Gaj P; Paziewska A; Bik W; Dąbrowska M; Baranowska-Bik A; Styczynska M; Chodakowska-Żebrowska M; Pfeffer-Baczuk A; Barcikowska M; Baranowska B; Ostrowski J
    J Alzheimers Dis; 2012; 32(1):157-68. PubMed ID: 22785395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease.
    Chaudhury S; Patel T; Barber IS; Guetta-Baranes T; Brookes KJ; Chappell S; Turton J; Guerreiro R; Bras J; Hernandez D; Singleton A; Hardy J; Mann D; ; Morgan K
    Neurobiol Aging; 2018 Feb; 62():244.e1-244.e8. PubMed ID: 29103623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degree of cognitive impairment does not signify early versus late mild cognitive impairment: confirmation based on Alzheimer's disease polygenic risk.
    Elman JA; Vuoksimaa E; Franz CE; Kremen WS;
    Neurobiol Aging; 2020 Oct; 94():149-153. PubMed ID: 32623261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating the role of the Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years.
    Andrews SJ; Eramudugolla R; Velez JI; Cherbuin N; Easteal S; Anstey KJ
    Alzheimers Res Ther; 2017 Mar; 9(1):16. PubMed ID: 28259165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.
    Leduc V; De Beaumont L; Théroux L; Dea D; Aisen P; Petersen RC; ; Dufour R; Poirier J
    Mol Psychiatry; 2015 Jul; 20(7):867-73. PubMed ID: 25023145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama.
    Villarreal AE; Grajales S; O'Bryant SE; Edwards M; López L; Montalván A; Britton GB;
    J Alzheimers Dis; 2016 Oct; 54(3):897-901. PubMed ID: 27567849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
    Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
    Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated progression from mild cognitive impairment to dementia among APOE ε4ε4 carriers.
    Xu WL; Caracciolo B; Wang HX; Santoni G; Winblad B; Fratiglioni L
    J Alzheimers Dis; 2013; 33(2):507-15. PubMed ID: 23247007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.